Lutz Stefan Freudenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lutz Stefan Freudenberg has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Bockisch
Klinik für Nuklearmedizin, Universitätsklinikum Essen
5 shared publications - Gerald Antoch
Universitätsklinikum Düsseldorf, Institut für Diagnostische und Interventionelle Radiologie, Düsseldorf
5 shared publications A. Bockisch
Klinik für Nuklearmedizin, Universitätsklinikum Essen, Deutschland
3 shared publicationsAndreas Bockisch
University Hospital Essen
3 shared publicationsJörg F Debatin
3 shared publications- Thomas Beyer
Medical University of Vienna, Vienna, Austria
3 shared publications
Latest Publications
- 5 December 2011
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 52 (Supplement) , 29S-35S
Subjective Perception of Radiation Risk
Physicians, medical staff, and patients, much like the general population, are becoming increasingly sensitized to the issue of radiation exposure from diagnostic or therapeutic procedures. The attitudes of patients undergoing diagnostic imaging procedures that use ionizing radiation vary widely. Patient perception of radiation dose strongly influences their acceptance of diagnostic examinations or therapies involving radioactivity. Here, we review perceptions and concerns about radiation and radioactivity by laypersons and medical experts. Several studies show that physicians are frequently poorly informed about radiation levels associated with nuclear medicine and radiologic examinations. In addition, patients' decisions against undergoing an imaging procedure are frequently based on partial and sometimes incorrect information. Thus, physicians must take the concerns of their patients seriously. From the literature and our own experience, we conclude that it is extremely important to thoroughly and carefully educate all involved in patient work-up about radiation exposure levels and perceived or actual health risks. Although the choice and timing of imaging examinations should always outweigh the risk that secondary illness will develop, the patients' concerns still must be alleviated.
- 5 December 2011
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 52 (Supplement) , 29S-35S
Subjective Perception of Radiation Risk
Physicians, medical staff, and patients, much like the general population, are becoming increasingly sensitized to the issue of radiation exposure from diagnostic or therapeutic procedures. The attitudes of patients undergoing diagnostic imaging procedures that use ionizing radiation vary widely. Patient perception of radiation dose strongly influences their acceptance of diagnostic examinations or therapies involving radioactivity. Here, we review perceptions and concerns about radiation and radioactivity by laypersons and medical experts. Several studies show that physicians are frequently poorly informed about radiation levels associated with nuclear medicine and radiologic examinations. In addition, patients' decisions against undergoing an imaging procedure are frequently based on partial and sometimes incorrect information. Thus, physicians must take the concerns of their patients seriously. From the literature and our own experience, we conclude that it is extremely important to thoroughly and carefully educate all involved in patient work-up about radiation exposure levels and perceived or actual health risks. Although the choice and timing of imaging examinations should always outweigh the risk that secondary illness will develop, the patients' concerns still must be alleviated.
- 12 April 2011
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 38 (S1) , 48-56
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer
124I-PET/CT has a high clinical potential in patients with differentiated thyroid cancer (DTC). Two aspects deserve special mention: staging of recurrent or residual disease and pretherapy dosimetry. Used in combination 124I-PET and CT allows foci of highly specific 124I uptake to be localized with a low radiation dose, which is specifically important in pretherapy diagnostics. In addition in the combination of FDG-PET and CT non-iodine-avid lesions may be detected and may be discriminated from simultaneously occurring iodine-positive lesions. In clinical applications, the pretherapy 124I-PET dosimetry may result in a significant alteration in the therapeutic procedure compared to standard therapy using fixed therapeutic activities. In this context, 124I-PET dosimetry is a useful procedure especially in advanced DTC, and allows the administration of safer and more effective radioiodine activities as well as earlier multimodal interventions compared to standard empirical protocols. This review summarizes the clinical data on 124I-PET/CT in patients with DTC, and addresses future prospects.
- 12 April 2011
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 38 (S1) , 48-56
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer
124I-PET/CT has a high clinical potential in patients with differentiated thyroid cancer (DTC). Two aspects deserve special mention: staging of recurrent or residual disease and pretherapy dosimetry. Used in combination 124I-PET and CT allows foci of highly specific 124I uptake to be localized with a low radiation dose, which is specifically important in pretherapy diagnostics. In addition in the combination of FDG-PET and CT non-iodine-avid lesions may be detected and may be discriminated from simultaneously occurring iodine-positive lesions. In clinical applications, the pretherapy 124I-PET dosimetry may result in a significant alteration in the therapeutic procedure compared to standard therapy using fixed therapeutic activities. In this context, 124I-PET dosimetry is a useful procedure especially in advanced DTC, and allows the administration of safer and more effective radioiodine activities as well as earlier multimodal interventions compared to standard empirical protocols. This review summarizes the clinical data on 124I-PET/CT in patients with DTC, and addresses future prospects.
- Open Access
- 11 August 2010
- Published by Verlag der Technischen Universitat Graz in Zeitschrift für Hochschulentwicklung
- Vol. 5 (2)
e-klar: Vom Nutzen der e-Learning Angebote in der Nuklearmedizin an deutschen Universitäten
E-klar: Vom Nutzen der e-Learning Angebote in der Nuklearmedizin an deutschen Universitäten
- 11 August 2010
- Published by Verlag der Technischen Universitat Graz in Zeitschrift für Hochschulentwicklung
- Vol. 5 (2)
Open Accesse-klar: Vom Nutzen der e-Learning Angebote in der Nuklearmedizin an deutschen Universitäten
E-klar: Vom Nutzen der e-Learning Angebote in der Nuklearmedizin an deutschen Universitäten
- 27 July 2010
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (12) , 2267-2276
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons
Renal radioiodine excretion is ~50% faster during euthyroidism versus hypothyroidism. We therefore sought to assess lesion dose/GBq of administered 131I activity (LDpA) in iodine-avid metastases (IAM) of differentiated thyroid carcinoma (DTC) in athyreotic patients after recombinant human thyroid-stimulating hormone (rhTSH) versus after thyroid hormone withdrawal (THW). We retrospectively compared mean LDpA between groups of consecutive patients (N = 63) receiving 124I positron emission tomography/computed tomography (124I PET/CT) aided by rhTSH (n = 27) or THW (n = 36); we prospectively compared LDpA after these stimulation methods within another individual. Data derived from serial PET scans and one CT scan performed 2–96 h post-124I ingestion. A mixed model analysis of covariance (ANCOVA) calculated the treatment groups’ mean LDpAs adjusting for statistically significant baseline intergroup differences: non-IAM were more prevalent, median IAM count/patient lower in cervical lymph nodes and higher in distant sites, median stimulated thyroglobulin higher, mean cumulative radioiodine activity greater and prior diagnostic scintigraphy more frequent in the rhTSH patients. Mean LDpAs were: rhTSH group (n = 71 IAM), 30.6 Gy/GBq; THW group (n = 66 IAM), 51.8 Gy/GBq. The difference in group means (rhTSH less THW), −21.2 Gy/GBq, was statistically non-significant (p = 0.1667). However, the 95% confidence interval of that difference (−51.4 to + 9 Gy/GBq) suggested a trend favouring THW. The within-patient comparison found 2.9- to 10-fold higher LDpAs under THW. We found some suggestions, but no statistically significant evidence, that rhTSH administration results in a lower radiation dose to DTC metastases than does THW. A large, well-controlled, prospective within-patient study should resolve this issue.
- 27 July 2010
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (12) , 2267-2276
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons
Renal radioiodine excretion is ~50% faster during euthyroidism versus hypothyroidism. We therefore sought to assess lesion dose/GBq of administered 131I activity (LDpA) in iodine-avid metastases (IAM) of differentiated thyroid carcinoma (DTC) in athyreotic patients after recombinant human thyroid-stimulating hormone (rhTSH) versus after thyroid hormone withdrawal (THW). We retrospectively compared mean LDpA between groups of consecutive patients (N = 63) receiving 124I positron emission tomography/computed tomography (124I PET/CT) aided by rhTSH (n = 27) or THW (n = 36); we prospectively compared LDpA after these stimulation methods within another individual. Data derived from serial PET scans and one CT scan performed 2–96 h post-124I ingestion. A mixed model analysis of covariance (ANCOVA) calculated the treatment groups’ mean LDpAs adjusting for statistically significant baseline intergroup differences: non-IAM were more prevalent, median IAM count/patient lower in cervical lymph nodes and higher in distant sites, median stimulated thyroglobulin higher, mean cumulative radioiodine activity greater and prior diagnostic scintigraphy more frequent in the rhTSH patients. Mean LDpAs were: rhTSH group (n = 71 IAM), 30.6 Gy/GBq; THW group (n = 66 IAM), 51.8 Gy/GBq. The difference in group means (rhTSH less THW), −21.2 Gy/GBq, was statistically non-significant (p = 0.1667). However, the 95% confidence interval of that difference (−51.4 to + 9 Gy/GBq) suggested a trend favouring THW. The within-patient comparison found 2.9- to 10-fold higher LDpAs under THW. We found some suggestions, but no statistically significant evidence, that rhTSH administration results in a lower radiation dose to DTC metastases than does THW. A large, well-controlled, prospective within-patient study should resolve this issue.
- 1 January 2010
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 49 (04) , 161-166
E-Learning in der Nuklearmedizin
Aim: To assess available e-learning concepts and programmes for nuclear medicine at university hospitals in Germany. Methods: All (34) departments of nuclear medicine at German university hospitals were asked to participate in an anonymized online survey. Questions were categorized into four topics: 1.) clinic and education; 2.) on-site strategies for e-learning; 3.) available e-learning offers and 4.) free text comments on experiences and expectations. All input was reviewed descriptively; free text was analyzed analytically. Results: The response rate was 56% (19/34). 13/19 responses indicated well-defined e-learning strategies, mainly to support frontal teaching courses. Future e-learning perspectives focus on clinical case studies with sufficient imaging materials. Only 7/19 university hospitals operate a centralized e-learning platform (e. g. Moodle). The acceptance of the available e-learning options by the students is considered relatively poor. Conclusions: Today e-learning concepts for nuclear medicine are available at selected university hospitals only. All responders wish to expand on e-learning but many report the lack of administrative support to do so. These data could be regarded as a basis for discussions of inter-university teaching scenarios. Ziel dieser Untersuchung ist es, für die Nuklearmedizin bundesweit die universitären e-Learning-Angebote und -Konzepte zu erfassen. Methoden: Ein Zugang zu einer anonymisierten Online-Umfrage wurde mit der Bitte um befristete Beantwortung an alle (34) nuklearmedizinischen Kliniken und Abteilungen an den deutschen Hochschulen geschickt. Die Fragen wurden in vier Themengebiete unterteilt: 1.) Klinik und Lehrveranstaltungen; 2.) e-Learning-Definitionen und -Strategien vor Ort; 3.) aktuelle e-Learning-Angebote vor Ort und 4.) Freitextkommentare zu Erfahrungen und Erwartungen. Die Auswertung der quantitativen Daten erfolgte deskriptiv, die Freitextangaben wurden inhaltsanalytisch ausgewertet. Ergebnisse: 19/34 Befragten (56%) nahmen an der Umfrage teil. 13/19 Lehrstühlen (68%) haben eine eigentliche e-Learning-Strategie, vorwiegend zur Unterstützung von Frontalunterricht. Zukünftige e-Learning-Ambitionen fokussieren auf klinischen Fallbeispielen mit Bildmaterial. Nur 7/19 Hochschulen betreiben eine zentrale e-Learning-Plattform (z. B. Moodle). Die Akzeptanz der e-Learning-Angebote bei den Studierenden wird als eher gering eingeschätzt. Schlussfolgerung: E-Learning-Konzepte für die Nuklearmedizin sind nur an ausgewählten Hochschulen vorhanden. Deren weitere Verwendung ist gewünscht, aber aus verschiedenen administrativen Gründen nicht immer zeitgemäß umsetzbar. Diese Daten sollen eine Basis für die Entwicklung von (ggfs. Universitäts-übergreifenden) Lehrszenarien sein und für einen professionellen Austausch.
- 1 January 2010
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 49 (04) , 161-166
E-Learning in der Nuklearmedizin
Aim: To assess available e-learning concepts and programmes for nuclear medicine at university hospitals in Germany. Methods: All (34) departments of nuclear medicine at German university hospitals were asked to participate in an anonymized online survey. Questions were categorized into four topics: 1.) clinic and education; 2.) on-site strategies for e-learning; 3.) available e-learning offers and 4.) free text comments on experiences and expectations. All input was reviewed descriptively; free text was analyzed analytically. Results: The response rate was 56% (19/34). 13/19 responses indicated well-defined e-learning strategies, mainly to support frontal teaching courses. Future e-learning perspectives focus on clinical case studies with sufficient imaging materials. Only 7/19 university hospitals operate a centralized e-learning platform (e. g. Moodle). The acceptance of the available e-learning options by the students is considered relatively poor. Conclusions: Today e-learning concepts for nuclear medicine are available at selected university hospitals only. All responders wish to expand on e-learning but many report the lack of administrative support to do so. These data could be regarded as a basis for discussions of inter-university teaching scenarios. Ziel dieser Untersuchung ist es, für die Nuklearmedizin bundesweit die universitären e-Learning-Angebote und -Konzepte zu erfassen. Methoden: Ein Zugang zu einer anonymisierten Online-Umfrage wurde mit der Bitte um befristete Beantwortung an alle (34) nuklearmedizinischen Kliniken und Abteilungen an den deutschen Hochschulen geschickt. Die Fragen wurden in vier Themengebiete unterteilt: 1.) Klinik und Lehrveranstaltungen; 2.) e-Learning-Definitionen und -Strategien vor Ort; 3.) aktuelle e-Learning-Angebote vor Ort und 4.) Freitextkommentare zu Erfahrungen und Erwartungen. Die Auswertung der quantitativen Daten erfolgte deskriptiv, die Freitextangaben wurden inhaltsanalytisch ausgewertet. Ergebnisse: 19/34 Befragten (56%) nahmen an der Umfrage teil. 13/19 Lehrstühlen (68%) haben eine eigentliche e-Learning-Strategie, vorwiegend zur Unterstützung von Frontalunterricht. Zukünftige e-Learning-Ambitionen fokussieren auf klinischen Fallbeispielen mit Bildmaterial. Nur 7/19 Hochschulen betreiben eine zentrale e-Learning-Plattform (z. B. Moodle). Die Akzeptanz der e-Learning-Angebote bei den Studierenden wird als eher gering eingeschätzt. Schlussfolgerung: E-Learning-Konzepte für die Nuklearmedizin sind nur an ausgewählten Hochschulen vorhanden. Deren weitere Verwendung ist gewünscht, aber aus verschiedenen administrativen Gründen nicht immer zeitgemäß umsetzbar. Diese Daten sollen eine Basis für die Entwicklung von (ggfs. Universitäts-übergreifenden) Lehrszenarien sein und für einen professionellen Austausch.
- 23 October 2009
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 118 (07) , 393-399
Thyroid Remnant Dose: 124I-PET/CT Dosimetric Comparison of rhTSH versus Thyroid Hormone Withholding Before Radioiodine Remnant Ablation in Differentiated Thyroid Cancer
Aim: Recombinant human thyroid-stimulating hormone (rhTSH) recently was approved as an alternative to thyroid hormone withholding (THW) to elevate TSH for thyroid remnant ablation in differentiated thyroid carcinoma patients. High ablation success rates are reported with diverse rhTSH-aided 131I activities. Improved renal function causes ∼50% faster radioiodine clearance under euthyroidism versus hypothyroidism. Knowledge of comparative remnant radioiodine kinetics, particularly the remnant radiation dose in Gy/GBq of administered 131I activity (RDpA), could assist in choosing rhTSH-aided ablative activities. Material and Methods: To compare the RDpA, determined through 124I-positron emission tomography/computed tomography (PET/CT), under the two stimulation methods, we retrospectively divided into two groups 55 consecutive totally-thyroidectomized, radioiodine-naïve patients. The rhTSH group (n=16) received 124I on thyroid hormone, 24 h after two consecutive daily intramuscular injections of rhTSH, 0.9 mg. The THW group (n=39) received 124I after weeks-long THW, when serum TSH first measured ≥25 mIU/L. We performed PET investigations 4 h, 24 h, 48 h, 72 h and 96 h and PET/CT 25 h after 124I administration. Results: Median stimulated serum thyroglobulin was 15 times higher (p=0.023) and M1 disease almost twice as prevalent (p=0.05) in rhTSH versus THW patients. Mean±standard deviation RDpA was statistically equivalent between the groups: rhTSH, 461±600 Gy/GBq, THW, 302±329 Gy/GBq, two-sided p=0.258. Conclusions: rhTSH or THW deliver statistically equivalent radiation doses to thyroid remnant and may be chosen based on safety, quality-of-life, convenience and pharmacoeconomic factors. Institutional fixed radioiodine activities formulated for use with THW need not be adjusted for rhTSH-aided ablation.
- 23 October 2009
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 118 (07) , 393-399
Thyroid Remnant Dose: 124I-PET/CT Dosimetric Comparison of rhTSH versus Thyroid Hormone Withholding Before Radioiodine Remnant Ablation in Differentiated Thyroid Cancer
Aim: Recombinant human thyroid-stimulating hormone (rhTSH) recently was approved as an alternative to thyroid hormone withholding (THW) to elevate TSH for thyroid remnant ablation in differentiated thyroid carcinoma patients. High ablation success rates are reported with diverse rhTSH-aided 131I activities. Improved renal function causes ∼50% faster radioiodine clearance under euthyroidism versus hypothyroidism. Knowledge of comparative remnant radioiodine kinetics, particularly the remnant radiation dose in Gy/GBq of administered 131I activity (RDpA), could assist in choosing rhTSH-aided ablative activities. Material and Methods: To compare the RDpA, determined through 124I-positron emission tomography/computed tomography (PET/CT), under the two stimulation methods, we retrospectively divided into two groups 55 consecutive totally-thyroidectomized, radioiodine-naïve patients. The rhTSH group (n=16) received 124I on thyroid hormone, 24 h after two consecutive daily intramuscular injections of rhTSH, 0.9 mg. The THW group (n=39) received 124I after weeks-long THW, when serum TSH first measured ≥25 mIU/L. We performed PET investigations 4 h, 24 h, 48 h, 72 h and 96 h and PET/CT 25 h after 124I administration. Results: Median stimulated serum thyroglobulin was 15 times higher (p=0.023) and M1 disease almost twice as prevalent (p=0.05) in rhTSH versus THW patients. Mean±standard deviation RDpA was statistically equivalent between the groups: rhTSH, 461±600 Gy/GBq, THW, 302±329 Gy/GBq, two-sided p=0.258. Conclusions: rhTSH or THW deliver statistically equivalent radiation doses to thyroid remnant and may be chosen based on safety, quality-of-life, convenience and pharmacoeconomic factors. Institutional fixed radioiodine activities formulated for use with THW need not be adjusted for rhTSH-aided ablation.
- 1 January 2008
- Vol. 47 (3) , 127-31
Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC.
Objective of this prospective study was to evaluate the role of somatostatin receptor scintigraphy (SRS) in advanced renal cell carcinoma (RCC) with respect to potential therapy with somatostatin analogue (SST-A) and to assess the response rate under therapy with SST-A. 16 patients with documented progression of histologically confirmed advanced RCC were included. Planar whole-body SRS was performed 4, 24 and 48 h post i.v. injection of 175-200 MBq 111In-pentetreoide. 5 and 25 h p.i. SPECT of thorax and abdomen were performed. Documentation of somatostatin receptor expression via SRS in >50% of known tumour lesions was the criteria for treatment start with SST-A (Sandostatin LAR-Depot 30 mg i.m. every four weeks). In 9/16 of the patients SRS showed at least one metastasis with moderate (n = 5) or intense (n = 4) tracer uptake. Lesion-based SRS evaluation showed only 12.1% (20/165) of all metastases. Most false-negative lesions were located in the lungs. In two patients, the majority of the known metastases was SRS positive and these patients received SST-A therapy. The first radiographic evaluation after a two-month interval showed progressive disease in both patients. We conclude that SRS is of limited value in staging of advanced RCC. In our patients SST-A did not result in a growth control of RCC. Consequently, the use of SST-A in advanced RCC seems to be no relevant therapeutic option.
- 1 January 2008
- Vol. 47 (3) , 127-31
Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC.
Objective of this prospective study was to evaluate the role of somatostatin receptor scintigraphy (SRS) in advanced renal cell carcinoma (RCC) with respect to potential therapy with somatostatin analogue (SST-A) and to assess the response rate under therapy with SST-A. 16 patients with documented progression of histologically confirmed advanced RCC were included. Planar whole-body SRS was performed 4, 24 and 48 h post i.v. injection of 175-200 MBq 111In-pentetreoide. 5 and 25 h p.i. SPECT of thorax and abdomen were performed. Documentation of somatostatin receptor expression via SRS in >50% of known tumour lesions was the criteria for treatment start with SST-A (Sandostatin LAR-Depot 30 mg i.m. every four weeks). In 9/16 of the patients SRS showed at least one metastasis with moderate (n = 5) or intense (n = 4) tracer uptake. Lesion-based SRS evaluation showed only 12.1% (20/165) of all metastases. Most false-negative lesions were located in the lungs. In two patients, the majority of the known metastases was SRS positive and these patients received SST-A therapy. The first radiographic evaluation after a two-month interval showed progressive disease in both patients. We conclude that SRS is of limited value in staging of advanced RCC. In our patients SST-A did not result in a growth control of RCC. Consequently, the use of SST-A in advanced RCC seems to be no relevant therapeutic option.
- 1 January 2008
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 47 (03) , 127-131
Somatostatin receptor scintigraphy in advanced renal cell carcinoma
Aims: Objective of this prospective study was to evaluate the role of somatostatin receptor scintigraphy (SRS) in advanced renal cell carcinoma (RCC) with respect to potential therapy with somatostatin analogue (SST-A) and to assess the response rate under therapy with SST-A. Patients, methods: 16 patients with documented progression of histologically confirmed advanced RCC were included. Planar whole-body SRS was performed 4, 24 and 48h post i.v. injection of 175–200 MBq 111In-pentetreoide. 5 and 25 h p.i. SPECT of thorax and abdomen were performed. Documentation of somatostatin receptor expression via SRS in >50% of known tumour lesions was the criteria for treatment start with SST-A (Sandostatin LAR®-Depot 30mg i.m. every four weeks). Results: In 9/16 of the patients SRS showed at least one metastasis with moderate (n = 5) or intense (n = 4) tracer uptake. Lesion-based SRS evaluation showed only 12.1% (20/165) of all metastases. Most false-negative lesions were located in the lungs. In two patients, the majority of the known metastases was SRS positive and these patients received SST-A therapy. The first radiographic evaluation after a twomonth interval showed progressive disease in both patients. Conclusions: We conclude that SRS is of limited value in staging of advanced RCC. In our patients SST-A did not result in a growth control of RCC. Consequently, the use of SST-A in advanced RCC seems to be no relevant therapeutic option. Ziel: Diese prospektive Studie untersucht die Rolle der Somatostatinrezeptor- Szintigraphie (SRS) bei Patienten mit fortgeschrittenen Nierenzellkarzinomen (RCC) im Hinblick auf eine mögliche Therapie mit Somatostatinanaloga (SST-A) und deren Response-Rate. Patienten, Methoden: 16 Patienten mit dokumentiertem Progress eines histologisch gesicherten RCC wurden eingeschlossen. Die planare Ganzkörper-SRS erfolgte 4, 24 und 48 h nach i.v.-Injektion von 175–200 MBq 111In-Pentetreoid. Fünf und 25 h p.i. wurde je eine SPECT von Thorax und Abdomen akquiriert. Bei einer Somatostatinrezeptor-Expression via SRS in >50% der bekannten Tumorläsionen wurde eine Therapie mit SST-A (Sandostatin LAR®-Depot 30mg i.m. alle vier Wochen) begonnen. Ergebnisse: In 9/16 der Patienten zeigte die SRS mindestens eine Metastase mit moderater (n = 5) oder intensiver (n = 4) Traceranreicherung. In der läsionsbasierten Auswertung zeigten sich jedoch nur 12,1% (20/165) der Metastasen. Die meisten falsch-negativen Läsionen fanden sich in der Lunge. Zwei Patienten, bei denen die Mehrzahl der Metastasen SRS-positiv waren, erhielten eine Therapie mit SST-A. Die erste radiologische Kontrolle nach zwei Monaten zeigte einen Progress der Erkrankung in beiden Patienten. Schlussfolgerung: Die SRS ist im Restaging von Patienten mit fortgeschrittenem RCC nur von begrenztem Wert. In unseren Patienten konnte mit SST-A kein Effekt auf das Größenwachstum der RCC erreicht werden. Dementsprechend scheint SST-A bei fortgeschrittenem RCC keine relevante therapeutische Option zu sein.
- 1 January 2008
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 47 (03) , 127-131
Somatostatin receptor scintigraphy in advanced renal cell carcinoma
Aims: Objective of this prospective study was to evaluate the role of somatostatin receptor scintigraphy (SRS) in advanced renal cell carcinoma (RCC) with respect to potential therapy with somatostatin analogue (SST-A) and to assess the response rate under therapy with SST-A. Patients, methods: 16 patients with documented progression of histologically confirmed advanced RCC were included. Planar whole-body SRS was performed 4, 24 and 48h post i.v. injection of 175–200 MBq 111In-pentetreoide. 5 and 25 h p.i. SPECT of thorax and abdomen were performed. Documentation of somatostatin receptor expression via SRS in >50% of known tumour lesions was the criteria for treatment start with SST-A (Sandostatin LAR®-Depot 30mg i.m. every four weeks). Results: In 9/16 of the patients SRS showed at least one metastasis with moderate (n = 5) or intense (n = 4) tracer uptake. Lesion-based SRS evaluation showed only 12.1% (20/165) of all metastases. Most false-negative lesions were located in the lungs. In two patients, the majority of the known metastases was SRS positive and these patients received SST-A therapy. The first radiographic evaluation after a twomonth interval showed progressive disease in both patients. Conclusions: We conclude that SRS is of limited value in staging of advanced RCC. In our patients SST-A did not result in a growth control of RCC. Consequently, the use of SST-A in advanced RCC seems to be no relevant therapeutic option. Ziel: Diese prospektive Studie untersucht die Rolle der Somatostatinrezeptor- Szintigraphie (SRS) bei Patienten mit fortgeschrittenen Nierenzellkarzinomen (RCC) im Hinblick auf eine mögliche Therapie mit Somatostatinanaloga (SST-A) und deren Response-Rate. Patienten, Methoden: 16 Patienten mit dokumentiertem Progress eines histologisch gesicherten RCC wurden eingeschlossen. Die planare Ganzkörper-SRS erfolgte 4, 24 und 48 h nach i.v.-Injektion von 175–200 MBq 111In-Pentetreoid. Fünf und 25 h p.i. wurde je eine SPECT von Thorax und Abdomen akquiriert. Bei einer Somatostatinrezeptor-Expression via SRS in >50% der bekannten Tumorläsionen wurde eine Therapie mit SST-A (Sandostatin LAR®-Depot 30mg i.m. alle vier Wochen) begonnen. Ergebnisse: In 9/16 der Patienten zeigte die SRS mindestens eine Metastase mit moderater (n = 5) oder intensiver (n = 4) Traceranreicherung. In der läsionsbasierten Auswertung zeigten sich jedoch nur 12,1% (20/165) der Metastasen. Die meisten falsch-negativen Läsionen fanden sich in der Lunge. Zwei Patienten, bei denen die Mehrzahl der Metastasen SRS-positiv waren, erhielten eine Therapie mit SST-A. Die erste radiologische Kontrolle nach zwei Monaten zeigte einen Progress der Erkrankung in beiden Patienten. Schlussfolgerung: Die SRS ist im Restaging von Patienten mit fortgeschrittenem RCC nur von begrenztem Wert. In unseren Patienten konnte mit SST-A kein Effekt auf das Größenwachstum der RCC erreicht werden. Dementsprechend scheint SST-A bei fortgeschrittenem RCC keine relevante therapeutische Option zu sein.
- 30 November 2007
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 115 (10) , 690-693
124-Iodine Positron Emission Tomography/Computed Tomography Dosimetry in Pediatric Patients with Differentiated Thyroid Cancer
Aim: Publications on 124-iodine (124I-)-positron emission tomography/computed tomography (PET/CT) dosimetry contain few if any data on pediatric patients with differentiated thyroid carcinoma (DTC). Aim of our study is to determine safety and informativeness of 124I-PET/CT dosimetry in DTC patients ≤18 yrs old. Material and Methods: We retrospectively analysed the data of 3 years of consecutive procedures (n-5) in children (n-4, 11-15 years). We acquired whole-body 124I-PET emission data 4, 24, 48, 72 and 96 hr, and 124I-PET/CT data 25 hr after oral 124I administration (22-26 MBq). Using these data, we calculated the thyroid remnant or metastatic lesion dose in Gy per GBq of 131-iodine (131I) (RDpA or LDpA, respectively). We measured with a well counter radiation counts of blood samples taken at 2, 4, 24, 48, 72 and 96 hr, and with an uncollimated NaI detector, whole-body clearance at approximately those times. Using these data, we calculated each patient's critical blood activity (CBA), the maximum 131I activity avoiding the putative >2Gy blood dose portending serious myelotoxicity. Results: Besides hypothyroid fatigue, no symptoms were noted. In 4 dosimetry procedures before the first radioiodine therapy, RDpAs were generally high (median 288 Gy/GBq, range 59-648 Gy/GBq). LDpAs (4 lymph node metastases) were much lower (median 6.5 Gy/GBq, range 1-9 Gy/GBq). CBAs were high (median 26 GBq, range 19-42, n=5). Disease management was modified or disease extent clarified in 2/4 patients. Conclusions: A standard adult 124I-PET/CT dosimetry protocol appears to be safe and informative in pediatric DTC patients.
- 30 November 2007
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 115 (10) , 690-693
124-Iodine Positron Emission Tomography/Computed Tomography Dosimetry in Pediatric Patients with Differentiated Thyroid Cancer
Aim: Publications on 124-iodine (124I-)-positron emission tomography/computed tomography (PET/CT) dosimetry contain few if any data on pediatric patients with differentiated thyroid carcinoma (DTC). Aim of our study is to determine safety and informativeness of 124I-PET/CT dosimetry in DTC patients ≤18 yrs old. Material and Methods: We retrospectively analysed the data of 3 years of consecutive procedures (n-5) in children (n-4, 11-15 years). We acquired whole-body 124I-PET emission data 4, 24, 48, 72 and 96 hr, and 124I-PET/CT data 25 hr after oral 124I administration (22-26 MBq). Using these data, we calculated the thyroid remnant or metastatic lesion dose in Gy per GBq of 131-iodine (131I) (RDpA or LDpA, respectively). We measured with a well counter radiation counts of blood samples taken at 2, 4, 24, 48, 72 and 96 hr, and with an uncollimated NaI detector, whole-body clearance at approximately those times. Using these data, we calculated each patient's critical blood activity (CBA), the maximum 131I activity avoiding the putative >2Gy blood dose portending serious myelotoxicity. Results: Besides hypothyroid fatigue, no symptoms were noted. In 4 dosimetry procedures before the first radioiodine therapy, RDpAs were generally high (median 288 Gy/GBq, range 59-648 Gy/GBq). LDpAs (4 lymph node metastases) were much lower (median 6.5 Gy/GBq, range 1-9 Gy/GBq). CBAs were high (median 26 GBq, range 19-42, n=5). Disease management was modified or disease extent clarified in 2/4 patients. Conclusions: A standard adult 124I-PET/CT dosimetry protocol appears to be safe and informative in pediatric DTC patients.
- 20 November 2007
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 35 (3) , 502-508
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET
This study assessed the ability of visual and quantitative 124-iodine positron emission tomography (124I PET) data to detect disseminated iodine-avid lung metastases (DILM) of differentiated thyroid cancer (DTC). Using “post-therapy” 131-iodine (131I) whole-body scintigraphy (TxWBS) and thoracic computed tomography (CT), we retrospectively divided 70 consecutive DTC patients undergoing 124I PET dosimetry ∼1 week before 131I therapy into subgroups positive (n = 7) or negative (n = 63) for DILM, defined as lung metastases visible on TxWBS but not thoracic CT. To determine whether 124I PET data could distinguish patients with versus without DILM, we compared these data with the TxWBS findings. The 124I PET data were acquired via whole-body PET scans ∼24 h after oral administration of 124I, 24 ± 2 MBq. Quantitative data comprised absolute lung 124I activity concentrations and lung-to-background (L/B) 124I uptake ratios. Only 1/7 DILM-positive patients had visible disseminated lung uptake. Absolute 124I lung uptake activities overlapped considerably between both groups and did not differ significantly (P = 0.150). Mean L/B ratios, however, differed significantly between the DILM-positive and negative groups (P < 0.001). Nevertheless, L/B ratios overlapped between the groups (0.62–1.37 versus 0.13–0.69). Quantitative analysis of 124I PET data using the L/B ratio is a promising tool to detect patients suspicious for DILM. However, L/B ratios overlapped between the groups to an extent that an unequivocal diagnosis based solely on this criterion was impossible in some patients. In those cases, additional diagnostic tests are necessary for diagnosis.
- 20 November 2007
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 35 (3) , 502-508
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET
This study assessed the ability of visual and quantitative 124-iodine positron emission tomography (124I PET) data to detect disseminated iodine-avid lung metastases (DILM) of differentiated thyroid cancer (DTC). Using “post-therapy” 131-iodine (131I) whole-body scintigraphy (TxWBS) and thoracic computed tomography (CT), we retrospectively divided 70 consecutive DTC patients undergoing 124I PET dosimetry ∼1 week before 131I therapy into subgroups positive (n = 7) or negative (n = 63) for DILM, defined as lung metastases visible on TxWBS but not thoracic CT. To determine whether 124I PET data could distinguish patients with versus without DILM, we compared these data with the TxWBS findings. The 124I PET data were acquired via whole-body PET scans ∼24 h after oral administration of 124I, 24 ± 2 MBq. Quantitative data comprised absolute lung 124I activity concentrations and lung-to-background (L/B) 124I uptake ratios. Only 1/7 DILM-positive patients had visible disseminated lung uptake. Absolute 124I lung uptake activities overlapped considerably between both groups and did not differ significantly (P = 0.150). Mean L/B ratios, however, differed significantly between the DILM-positive and negative groups (P < 0.001). Nevertheless, L/B ratios overlapped between the groups (0.62–1.37 versus 0.13–0.69). Quantitative analysis of 124I PET data using the L/B ratio is a promising tool to detect patients suspicious for DILM. However, L/B ratios overlapped between the groups to an extent that an unequivocal diagnosis based solely on this criterion was impossible in some patients. In those cases, additional diagnostic tests are necessary for diagnosis.